Coronavirus, WHO suspends tests on the use of hydroxychloroquine: “Higher mortality rate” – La Stampa


The World Health Organization has discontinued anti-Covid-19 treatment with hydroxychloroquine for the time being following studies that have demonstrated its high mortality rate. This was announced by the WHO Director-General, Tedros Adhanom Ghebreyesus. “Friday The Lancet published a monitoring study on hydroxychloroquine and chloroquine and its effects on Covid-19 patients who were hospitalized. The authors reported that among patients who received the drug, alone or with a macrolide, they estimated a higher mortality rate, “explained Ghebreyesus. However, the two drugs have always been considered safe for the treatment of malaria and autoimmune diseases.

The WHO then reiterated the need to test, track and isolate the positives and respect the rules of social distancing. “There is a risk of a second wave among the countries that are managing to control the virus – said Mike Ryan, head of WHO’s health emergencies program – but I must stress that this virus can skyrocket at any time.”

No greater risk for children affected by Kawasaki
WHO also intervened on the consequences of coronavirus on Kawasaki affected children who in recent weeks had received the attention of social networks. The organization said that “there is currently no scientific evidence that children who have had Kawasaki disease are at greater risk of contracting Covid 19 or a repeat offender.” Some studies describe an acute multisystem inflammatory syndrome between children and adolescents, associated with positivity for Covid 19 or the presence of antibodies that would seem to share some characteristics with Kawasaki but, according to the ECDC and WHO, it would be a different form from Kawasaki. to be defined.

Source link


Please enter your comment!
Please enter your name here